Study identifier:D9618C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 6-month randomized, double-blind, parallel-group, multicentre, placebo-controlled Phase II study to compare anti-asthmatic effect and safety of esomeprazole (Nexium®) 40 mg twice daily or 40 mg once daily with placebo in adults with asthma
asthma, GERD
Phase 2
No
Esomeprazole, Placebo
All
961
Interventional
18 Years - 70 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Feb 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to determine whether treatment with esomeprazole for 6 months will improve asthma in adult patients with moderate to severe asthma and symptoms of gastroesophageal reflux disease.
Location
Location
CIUDAD DE BUENOS AIRES, Argentina, Argentina
Location
MONTE GRANDE, Buenos Aires, Argentina
Location
QUILMES, Buenos Aires, Argentina
Location
Córdoba, Córdoba, Argentina
Location
Córdoba, Córdoba, Argentina, Argentina
Location
ROSARIO, SANTA FE, Argentina
Location
ROSARIO, SANTA FE, ARGENTINA, Argentina
Location
San Miguel De Tucumán, Tucumán, Argentina, Argentina
Arms | Assigned Interventions |
---|---|
Experimental: Esomeprazole 40 mg twice daily | Drug: Esomeprazole Esomeprazole 40 mg twice daily |
Experimental: Esomeprazole 40 mg once daily | Drug: Esomeprazole Esomeprazole 40 mg once daily |
Placebo Comparator: Placebo | Drug: Placebo Placebo twice daily |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.